

## **ASX RELEASE**

### **ADMEDUS LTD TO HOST INVESTOR WEBINAR**

- Admedus Investor Webinar on Friday the 30<sup>th</sup> of October
- 2pm AEST Sydney/Melbourne time; 1pm AEST Brisbane time, 11am WST Perth time

#### **Perth, Australia 29<sup>th</sup> October, 2015**

Admedus (ASX:AHZ) has today announced that it will hold an investor webinar on Friday, 30 October 2015 to discuss the Company's 4C, which will also be released on that day.

The webinar will be an opportunity to provide a business update and further insight into the Company's outlook and priorities. The webinar will be live and interactive and include an investor Q&A session at the end of the presentation.

#### **Webinar details**

**Date:** Friday, 30 October

**Time:** 2pm AEST Sydney/Melbourne time; 1pm AEST Brisbane time, 11am WST Perth time

**Please register to attend the webinar at:**

<http://webcasting.brrmedia.com/broadcast/56304ccbb6c073d9055f761d>

Once you have registered to attend the webinar via the link above, you will receive a confirmation email with the webcast link and dial-in details.

Follow us:

Twitter: @Admedus

Facebook: [www.facebook.com/pages/Admedus](http://www.facebook.com/pages/Admedus)

#### **For more information, please contact:**

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

#### **Media:**

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: [scooper@admedus.com](mailto:scooper@admedus.com)

**Media Europe**

FTI Consulting  
Simon Conway / Victoria Foster Mitchell  
Tel: +44 (0) 20 3727 1000  
admedus@fticonsulting.com

**About Admedus Limited**

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on [www.admedus.com](http://www.admedus.com)